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Abstract
Objective: To evaluate if a standardized combination therapy regimen, utilizing 3
monthly ranibizumab injections followed by navigated laser photocoagulation,
reduces the number of total ranibizumab injections required for treatment of diabetic
macular edema (DME).
Research Design and Methods: A 12-month, prospective comparison of 66
patients with center-involving DME: 34 patients with combination therapy were
compared to 32 patients treated with ranibizumab monotherapy. All patients initially
received 3 monthly ranibizumab injections (loading phase) and additional injections
pro re nata (PRN). Combination therapy patients additionally received navigated
laser photocoagulation after the loading phase. Main outcome measures were
mean number of injections after the loading phase and change in BCVA from
baseline to month 12.
Results: Navigated laser combination therapy and ranibizumab monotherapy
similarly improved mean BCVA letter score (+8.41 vs. +6.31 letters, p50.258). In
the combination group significantly less injections were required after the 3 injection
loading phase (0.88¡1.23 vs. 3.88¡2.32, p,50.001). By month 12, 84% of
patients in the monotherapy group had required additional ranibizumab injections
as compared to 35% in the combination group (p,50.001).
Conclusions: Navigated laser combination therapy demonstrated significant visual
gains in most patients. Retreatment rate and number of injections were significantly
lower compared to ranibizumab monotherapy and compared to the results of
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conventional laser combination therapy previously reported in pivotal anti-VEGF
studies.
Introduction
The development of antibody-derived inhibitors of vascular endothelial growth
factor (VEGF), such as ranibizumab (Rbz), have dramatically changed the
management of DME and progressively replaced Macular Laser Therapy (MLT) as
a first-line treatment option.
Major randomized controlled trials have demonstrated that intravitreal anti-
VEGF injections not only help to maintain visual acuity in patients suffering from
fovea-involving DME, but can also improve vision significantly (by an average of
at least six letters in the first year) [1–5].
The same trials have also documented that frequent intravitreal injections, on
the order of seven to twelve in the first year and slightly fewer in subsequent years,
were needed to accomplish and maintain these results [4, 6].
The significant treatment burden placed on patients, doctors, healthcare
providers and payers, as well as, reports of inferior results with inadvertent under-
treatment in everyday clinical settings, highlight the need for a treatment
paradigm providing optimal visual outcomes with fewer injections [7, 8].
While conventional MLT, applied as monotherapy, demonstrated a stabilizing
effect on vision at a low treatment frequency in the ETDRS and subsequent
studies, so far no clear benefit has been demonstrated when added to Anti-VEGF,
either with respect to enhanced visual acuity gains or reduced injection burden
[4, 6, 9, 10].
A new computer-guided technology for navigated MLT, developed to overcome
some of the limitations of manual, slit-lamp based laser application, has recently
become available (Navilas Laser System, OD-OS GmbH, Teltow, Germany) [11–
15].
Using digital planning and image-guidance, navigated laser therapy has
demonstrated a significantly higher accuracy in laser spot application, with the
potential to reduce the retreatment rate compared to conventional laser
monotherapy [11–15].
We hypothesized, that the potential for earlier disease stabilization with
navigated MLT could also translate into earlier stabilization of Anti-VEGF visual
gains and therefore reduced Anti-VEGF retreatment rate and overall injection
burden.
To evaluate this hypothesis, we developed a standardized treatment regimen
based on the pro re nata (PRN) scheme of the European approval for ranibizumab
and a navigated MLT application after the first three monthly injections.
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Study Population and Methods
Study Design
This was a 12-month, prospective comparison of 66 patients with center-involving
DME conducted at the Department of Ophthalmology, Ludwig-Maximilians-
University, Munich, Germany. Patients either received a combination treatment
consisting of ranibizumab injections plus navigated MLT or ranibizumab
monotherapy as two co-existing standard treatments. Physicians that had not
undergone training with navigated MLT performed Rbz monotherapy, while
trained physicians performed combination therapy, leading to a quasi-random
assignment of patients to their respective cohort.
The study was conducted in accordance with the Declaration of Helsinki.
Approval was obtained from the institutional review board and written informed
consent provided by each patient.
Participants
Consecutive patients were enrolled in 2011 and 2012 from the outpatient clinic of
the Department of Ophthalmology, Ludwig-Maximilians-University, Munich.
Key eligibility criteria for all participants were: female or male with a minimum
age of 18 years and a diagnosed diabetes mellitus Type I or II with clinically
significant DME according to the criteria of the ETDRS [16]. Further criteria
included (1) best-corrected visual acuity (BCVA) of at least 10 letters on the
ETDRS chart, (2) central retinal thickening (CRT) of at least 400 mm (with foveal
involvement); measured by spectral domain OCT [(SD-OCT) Spectralis OCT,
Heidelberg Engineering GmbH, Heidelberg, Germany] and, based on clinical
examination made by two experienced retina specialists, (3) no ischemic
maculopathy seen in fluorescein angiography, (4) no severe proliferative diabetic
retinopathy (PDR) or macular edema due to other underlying retinal vascular
disease, vitreomacular traction or epiretinal membranes, (5) no previous anti-
VEGF, MLT or other major ocular surgeries within the last 4 months, (6) no pre-
existing ocular conditions that would preclude improvement in visual acuity
despite reduction of the edema, (7) no pregnant or lactating subjects and (8) no
subjects currently enrolled in other clinical trials.
Standardized Treatment Regimen
All patients underwent a baseline examination including best-corrected visual
acuity, slit-lamp examination, dilated fundoscopy, OCT-imaging and measure-
ment and fluorescein angiography. We assessed BCVA at every study visit using
ETDRS charts at a starting distance of 4 meters. OCT imaging was performed on
spectral domain OCT with eye-tracking and rescan support in follow-up
measurements (Spectralis OCT, Heidelberg Engineering GmbH, Heidelberg,
Germany).
After eligibility was confirmed, all participants then received intravitreal
injection therapy (IVT) with 0.5 mg ranibizumab (Rbz) closely following the
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European label, which details a pro re nata (PRN) protocol based on the
RESTORE study with or without adjunct MLT. It must be noted, that this
treatment paradigm differs in this regard from the U.S. label for 0.3 mg
ranibizumab in DME.
As outlined above, navigated MLT was applied only to cohort 2, while cohort 1
received Rbz monotherapy:
- Cohort 1 – Ranibizumab Monotherapy: Patients were initially treated with
three anti-VEGF injections in one-month intervals. After the ‘‘loading phase’’
injections were delivered pro re nata (PRN).
- Cohort 2 – Navigated Laser Combination Therapy: Three initial anti-VEGF
injections were given in one-month intervals with a Navilas navigated MLT
delivered one month after the third injection if CRT had decreased to 445 mm
or below. Otherwise one more injection was given and navigated MLT applied
four weeks after. Further anti-VEGF injections were delivered pro re nata
(PRN) as described below.
According to the PRN scheme, injection therapy was paused after the loading
phase in patients who demonstrated stable BCVA and CRT on two consecutive
examinations, or if the BCVA reached 85 ETDRS letters or the DME was
completely resolved (CRT,300 mm). Patients were followed monthly with BCVA
and CRT obtained at each visit and intravitreal injections were resumed if a
reduction in BCVA of more than 5 letters compared to baseline BCVA or an
increase of CRT of at least 20% was observed. Retreatment was continued until
BCVA and CRT were again stable for at least two consecutive visits.
Intravitreal injections
Patients received intravitreal injections of ranibizumab as delineated above.
Injections were performed according to a standard procedure: topical antibiotics
were used both pre and post injection under aseptic operating theatre conditions.
After draping a 30-gauge needle was inserted into the vitreous cavity through pars
plana and 0.5 mg/mL RBZ were injected. The cannula was then withdrawn and a
sterile cotton tip was placed on the injection site.
Navigated MLT
Navigated MLT procedures were performed with the scanning slit laser
photocoagulator, Navilas Laser System (OD-OS GmbH, Teltow, Germany), which
was CE-marked and approved by the US Food and Drug Administration in 2009.
Its principal operation has been described elsewhere [13]. In brief, it combines
imaging, laser application planning, and treatment in a computer-based device. It
fundamentally differs from other laser devices by using a scanning slit-based
principle to acquire and display high-resolution images on a touch screen
monitor.
Navigated Laser and Ranibizumab in DME
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Navigated MLT procedures in this study were digitally planned on Color and
FA images acquired by the instrument and/or imported OCT thickness maps by
placing single spots and grid patterns according to ETDRS guidelines. The spot
size was typically set to 100 mm and applied with a pulse duration of 100 ms.
Based on color snap images taken during treatment, laser power was individually
adjusted to values around 100 mW to achieve a pale grayish, barely visible laser
burn. The treatment was administered using the plan overlay and laser-beam
prepositioning features of the device.
In cases were navigated MLT and anti-VEGF injections were given on the same
day, we always delivered navigated MLT first and anti-VEGF injections at
minimum two hours afterwards.
Statistical Methods
All data were collected in a MS-Excel 2010 spreadsheet (Microsoft Corporation,
Redmond, WA) and analyzed using the Statistical Package for Social Sciences
version 21.0 for Windows (IBM, New York, USA).
Results
A total of 66 patients were included into this prospective comparison: 34 patients
received ranibizumab/navigated laser combination therapy and 32 patients
received ranibizumab monotherapy. A total of 99 patients were initially screened
for this study of which 33 dropped out as they either did not meet all the inclusion
criteria or refused to take part in this study. From the 66 patients that were
included, none dropped out at a later stage over the study period or completely
missed a follow-up. All data gathered at follow-ups were within a ten day time
frame of the protocol requirements and therefore included in our study results.
(Fig. 1)
Baseline characteristics, which are similar in both cohorts, are summarized in
Table 1. Mean baseline BCVA was 30.8¡12.6 and 24.6¡14.4 letters for
combination and monotherapy cohorts, respectively (p50.065). Mean baseline
CRT values were 441¡162 and 444¡117, respectively (p50.928).
Visual Acuity and CRT development
Immediately following the baseline exam, treatment was initiated with three
ranibizumab intravitreal injections spaced approximately one month apart. By
one month after this loading phase, both cohorts had reached equivalent and
significant BCVA gains (Fig. 2, 3 months time point). Combination therapy eyes
had improved by 7.9¡7.6 letters and monotherapy eyes had improved by
5.5¡5.8 letters (p50.150).
Navigated MLT was applied to combination therapy eyes 115¡113 days mean
after starting the ranibizumab intravitreal loading phase injections.
Navigated Laser and Ranibizumab in DME
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Fig. 1. Flow chart of the study. Enrollment, Assignment and Follow-up of the patients that were included in
this prospective comparison of combined navigated macula laser therapy and mono anti-VEGF therapy.
doi:10.1371/journal.pone.0113981.g001
Table 1. Baseline Characteristics of the Sample.
Navilas + Ranibizumab n534 Ranibizumab Monotherapy n532 Test for difference (P-Value)
Mean age ¡ SD, years 64.9¡11.6 68.2¡11.3 p50.255
Gender (% (n) female) 47% (16) 40% (13) p50.605
Mean BCVA ¡ SD, ETDRS letter score 30.8¡12.6 24.6¡14.4 p50.065
Mean CRT ¡ SD, mm 441¡162 444¡117 p50.928
SD, standard deviation; CRT, central retinal thickness; BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.
doi:10.1371/journal.pone.0113981.t001
Navigated Laser and Ranibizumab in DME
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Initial BCVA gains remained stable in the PRN phase through months 6 and 12,
with 6 month values of +7.1¡6.2 letters and +7.6¡6.5 letters in combination
therapy and monotherapy eyes, respectively (p50.750).
By month 12 combination therapy eyes had improved 8.4¡8.3 letters and
monotherapy eyes had improved 6.3¡6.5 letters. While there is a trend towards a
better mean BCVA outcome for the combination therapy cohort, this difference
did not reach statistical significance (p50.258).
Categorized BCVA outcomes are detailed in Table 2. By month 12, 47% of
combination therapy eyes vs. 31% of monotherapy eyes had gained 10 letters or
more and 21% vs. 9% had gained 15 letters or more. One patient in the
combination therapy cohort had lost more than 15 letters and one patient in the
monotherapy arm had lost more than 10 letters (3% of patients each).
Improvements in visual acuity were reflected by significant anatomic
improvement from baseline: in the combination therapy arm central retinal
thickness improved from 441¡162 to 313¡98 (mean improvement of
2129¡170 um) and in the monotherapy cohort from 444¡117 to 339¡82
(mean improvement of 2105¡107 um (Fig. 2); group difference p50.487).
Retreatment rates and number of injections
Injection retreatment data in both cohorts was subjected to Kaplan-Meier
analysis, which shows an early separation of the two curves (Fig. 3). The median
time to retreatment calculated over all monotherapy eyes was 63 days, while at the
Fig. 2. Course of best-corrected visual acuity (BCVA) and central retinal thickness (CRT). (A) Change in best-corrected visual acuity (BCVA) and (B)
change in central retinal thickness (CRT) during 12 months follow-up (Error bars: 95% CI). Eyes received three Rbz loading injections and combination
therapy eyes additionally received Navigated MLT 115¡113 days mean from baseline. Thereafter, all eyes received PRN injections. Three months from
baseline, combination therapy eyes had improved by a mean 7.9¡7.6 letters and monotherapy eyes had improved by 5.5¡5.8 letters (difference p50.150)
and remained stable through the PRN phase. Twelve-month values were 8.4¡8.3 letters and 6.3¡6.5 letters, respectively (difference p50.258). Similarly,
during 12 months CRT in the combination therapy cohort had improved by a mean -129¡170 mm and in the monotherapy cohort from by a mean
2105¡107 mm (difference p50.487).
doi:10.1371/journal.pone.0113981.g002
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end of the study at 10 months after the third injection (12 months of total follow-
up) the median had not been reached in the combination therapy cohort. At the
end of the study the combination therapy cohort had a significantly higher
proportion of patients that required no further injections after the anti-VEGF
loading phase than the monotherapy cohort: 65% vs. 16% (p#0.001). The
reduced retreatment rate in the combination therapy cohort corresponds to a
significantly lower requirement for injections as compared to monotherapy:
0.9¡1.2 vs. 3.9¡2.3 after the loading phase, 3.9¡1.3 vs. 6.9¡2.3 total during 12
months follow-up, p#0.001 for both comparisons. (Table 3)
At 12 months from baseline, combination therapy eyes received a mean of
1.24¡0.43 navigated laser treatments. Twenty-six eyes received the minimum of
one navigated laser treatment and eight eyes received two treatments.
No adverse effects of intravitreal injections or navigated laser were observed
during the study.
Fig. 3. Kaplan-Meier analysis of injection retreatment after the last loading phase injection. A
significantly higher proportion of Rbz monotherapy patients (84%) required injection retreatment compared to
the navigated laser combination therapy cohort (35%, difference p#0.001). Median time to retreatment was
63 and.300 days (median not reached during follow-up), respectively.
doi:10.1371/journal.pone.0113981.g003
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2 Mean ¡ SD 8.4¡8.3 6.3¡6.5 p50.258
2 Median (range) 9 (221 to +25) 6.5 (212 to +17)
295% CI for mean 5.51, 11.31 3.99, 8.64
Categorized BCVA outcome (ETDRS letter
score)
2 Gain: 15 letters or more 21% (7) 9% (3) p50.210
2 Gain: 10 letters or more 47% (16) 31% (10) p50.195
2 Loss: 10 letters or more 3% (1) 3% (1) p50.336
2 Loss: 15 letters or more 3% (1) 0% (0) p50.966
Mean CRT ¡ SD (mm)
2 Baseline 441¡162 444¡117 p50.928
212 months 313¡98 339¡82 p50.255
SD, standard deviation; CI, confidence interval; CRT, central retinal thickness; BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic
Retinopathy Study.
doi:10.1371/journal.pone.0113981.t002





Test for difference - P-
Value
Number of injections after loading phase (3x ranibizumab)
2 Mean ¡ SD 0.9¡1.2 3.9¡2.3 p#0.001
2 Median (range) 0 (0 to 4) 4 (0 to 8)
295% CI for mean 0.45, 1.31 3.04, 4.71
2 Difference in mean number of injections vs. Ranibizumab
Monotherapy (n, %)
23.0, 277%
Total number of injections at 12 month including loading
phase
2 Mean ¡ SD 3.9¡1.3 6.9¡2.3 p#0.001
2 Median (range) 3 (3 to 7) 7 (3 to 11)
295% CI for mean 3.47; 4;35 6.04; 7.71
2 Difference in mean number of injections vs. Ranibizumab
Monotherapy (n, %)
23.0, 243%
Proportion of eyes with no need for injections after
loading phase (%, n)
65%, 22 16%, 5 p#0.001
Median time to retreatment (months) .10 (not reached during
follow-up)
2.1
Number of navigated laser treatments Mean, Median
(range)
1.24, 1 (1–2)
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Discussion
Diabetic macular edema is one of the most common reasons for significant visual
impairment in the western world. It may affect people from all age groups and
strongly affects patient’s quality of life [9, 17].
The development of anti-VEGF therapeutics placed an important treatment
option into the hands of the retinal physician to rapidly stabilize or even restore
vision in DME. However, it is now apparent that chronic intravitreal injection
therapy is needed to preserve or slightly extend these visual gains [4, 6].
This 12-month, prospective comparison on the efficacy of a standardized
combination therapy regimen (three ranibizumab injections followed by
navigated MLT) compared to anti-VEGF monotherapy, demonstrated that the
combination of Rbz and navigated MLT may be superior in terms of retreatment
rate and overall injection burden.
Both cohorts achieved significant and comparable visual gains attributable to
the Rbz loading phase. Combination therapy gains were in trend higher (8.6
ETDRS letters) and non-inferior to Rbz monotherapy gains (6.3 letters, difference
n.s.). Combination therapy patients had a significantly lower retreatment rate
with 65% (vs. 16%) of patients not receiving further Rbz after loading/navigated
MLT. On average, less than one injection was required after Rbz loading,
corresponding to a reduction of 3 injections vs. Rbz monotherapy.(Table 3)
Therefore, the application of navigated MLT after Rbz loading appears to reduce
the injection burden considerably without compromising anti-VEGF visual gains.
With regard to similar combination therapies using conventional laser instead
of navigated MLT, evidence from pivotal trials is inconclusive. In the RESTORE
study, patients received a minimum of 3 initial injections until BCVA was stable at
two consecutive visits and in one arm of this study patients received conventional
laser photocoagulation at baseline and as needed at 3 month intervals [9]. As in
this study, follow-up was 12 months from baseline, conventional laser
combination therapy and Rbz monotherapy reached average BCVA gains of 6.1
and 5.9 ETDRS letters, requiring a mean of 7.0 and 6.8 injections, respectively.
These insignificant differences between study arms indicate no benefit from
adding conventional laser. Similarly, the DRCR.net trial using a different
treatment and retreatment algorithm, did not demonstrate significant differences
between a prompt laser arm and a deferred laser arm (no laser in 70% of patients
during year one) [10]. Median visual gains were 9 letters each achieved with 8 and
9 injections median, respectively. In contrast, the smaller READ-2 study did show
a reduced number of 4.9 vs. 9.3 injections in a 24-month period, when adding a
mean number of 2.7 conventional laser treatments to anti-VEGF therapy.
However, visual gains were slightly, but not significantly lower in the combination
arm (6.8 vs. 7.7 letters gain) [18].
In summary, no consistent benefit from added conventional laser can be
inferred. Reasons, besides a different study objective, may include the lack of
standardization and accuracy of slit-lamp based laser application in the clinical
setting.
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Navigated MLT was developed to overcome these limitations with multimodal
planning and treatment functions (‘‘eye tracking’’), e.g. accurately pinpointing
microaneurysms on fluorescein angiography images and outlining edematous
areas on OCT thickness maps for subsequent grid laser treatment. During
treatment each spot is prepositioned and tracked with the physician remaining in
control. We observed a significantly lower retreatment rate of navigated MLT
monotherapy compared to conventional laser in a previous study, suggesting
stabilization may be reached earlier after navigated therapy (i.e. frequently after
the first treatment).
In contrast, most Rbz monotherapy patients in this study required retreatment
within the first 3 months after Rbz loading (Median: 63 days). This may highlight
the importance of using a standardized, fast-acting MLT that achieves most of its
effects with the first treatment in order to reduce the requirements for additional
injections.
Our study supports the results of a similar study conducted by the University of
California in San Diego that included patients that had been treated with a similar
standardized combination therapy regimen utilizing navigated MLT and
bevacizumab. In these patients, an average of 4 injections were necessary during
12 months follow up period [19].
Generally, while these results suggest a compelling benefit of adding navigated
MLT to anti-VEGF therapy, they await confirmation by larger multicentric,
randomized controlled trials.
Considering the developments on drug based therapies together with the
promising results of the presented study, we believe that the combination of two
well-studied treatment modalities, intravitreal Rbz as well as navigated MLT offers
the potential to improve DME management even further.
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